Human Immunodeficiency Virus (HIV): Competitive Landscape to 2026

Human immunodeficiency virus (HIV) is a retrovirus that impairs and destroys the host’s immune system, specifically targeting CD4 cells. Once an infected person has a CD4 cell count of less than 200 cells/μL, HIV has developed into acquired immunodeficiency syndrome (AIDS).

This report provides an assessment of the pipeline, clinical, and commercial landscape of HIV. Overall, GlobalData expects new drug approvals to drive HIV market growth over the next decade (2016–2026).

Scope

GlobalData’s Human Immunodeficiency Virus (HIV): Competitive Landscape to 2026 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the slide deck include:

• Pipeline Assessment—regional breakdown, promising late-stage products, early-stage pipeline by molecule type

• Clinical Trials Assessment—trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics

• Commercial Assessment—leading marketed products, current and future players

• Competitive Landscape Analysis—key market events (2016–2026)

Reasons to buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global HIV market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HIV market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies mentioned

Gilead Sciences

ViiV Healthcare

GlaxoSmithKline

Pfizer

Shionogi

Janssen (Johnson & Johnson)

Bristol-Myers Squibb

Merck & Co

AbbVie

TaiMed Biologics

Theratechnologies

CytoDyn

Torii Pharmaceuticals

Japan Tobacco

Frontier Biotechnologies

Table of Contents

1 Preface

1.1 Table of Contents

1.2 Abbreviations

1.3 Related Reports

1.4 Upcoming Related Reports

2 Executive Summary

2.1 Key Findings

2.2 Key Events

3 Introduction

3.1 Report Scope

3.2 Disease Overview & Epidemiology

4 Pipeline Assessment

4.1 Pipeline Overview

4.2 Pipeline Breakdown by Region/Country

4.3 Pipeline Breakdown by Molecule Type and Target

4.4 Drug Review Designations

4.5 Products in Clinical Development

5 Clinical Trial Assessment

5.1 Clinical Trials Overview

5.2 Top Sponors of Clinical Trials in HIV

5.3 Trial Breakdown by Region

5.4 Therapy Area Perspective

5.5 Enrollment Analytics

6 Commercial Assessment

6.1 Leading Marketed Products

6.2 Current & Future Players

7 Competitive Landscape Analysis (2016–2026)

7.1 Events and Segmentation Overview

7.2 US

7.3 5EU

7.4 Japan

7.5 Brazil

7.6 China

8 Appendix

8.1 Sources

8.2 Methodology

8.3 Key Events Included in the Analysis

8.4 About the Authors

8.5 About GlobalData

8.6 Contact Us

8.7 Disclaimer

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports